The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Thanks Caravan and Ffd. I went to get quotes and got 1.88 to buy 1.71 to sell, so more like 9-10%. Still a stretch. It doesn't seem to be generating much volume either way. Hope your reasons for bullishness are correct. Convinced there's value in its assets, but the directors aren't doing a great job of selling the upside
Been in this share since early Feb, so not long. Thought it was undervalued then. -20% later and I'm not so sure. It seems too undervalued, what's going on? There seems to be minimal interest and the spread is a crazy 14%, hardly going to encourage investors/traders... Last production was underwhelming and oil has come off a bit, but surely it's worth more than current market cap?! Remaining patient.
Excellent post matml74.
That's all I could find too... Concerning.
https://www.thetimes.co.uk/article/smith-nephew-corruption-inquiry-asked-for-documents-f3f6d8qrw
Behind a paywall though.
Good steady progress...
https://twitter.com/IsaacAim/status/1480885562135482369?t=pUoitFl10ScQW1_Smqp0iw&s=19
My average is 137. Not selling. Next step is to get more info in half year report and have better understanding of the situation. Not just in regard the submission, but the other business lines too.
Perhaps a wise move since they'll not make the same false start with patch submission and will have been to crack on with other project
From 3 Nov RNS:
The Company has been advised that it would be better to run two applications relying on the same data in series rather than in parallel to avoid compromising either submission. As such, the patch 510k submission will now follow on from the graft 510k approval. This revised regulatory submission strategy also allows the Company to focus resource on a feasibility study into Peripheral Artery Disease and Critical Limb Ischemia devices for which the Company was successful in competing for Innovate UK grant finance. This exciting new project, which the Board hopes will add to the product pipeline, will be undertaken during the first quarter of 2022.
Good post re: 501k summary, thanks. I agree, pi panic, nervous ahead of the update...
In RNS: A further update on the agreed process with the FDA and the likely new timelines for approval of the 510k will be made in due course.
It'll come. Possibly holding off on half year update so they include more detail on what is obviously an ongoing moving situation
Were 11 Dec last year I should clarify!
And any II buys like Dowgate will be interesting
Half year results were 11 Dec, so due soon. If they're positive in outlook, with well articulated strategy and financial runway, we should bounce when we're all the wiser.
Well it wings for the sleepiest c-19 stock on AIM... How long will it rest before it wakes up with a bang? Surely positive drivers here... I'll hold, top up and wait.
This is a disappointing drop. My top up yesterday at 107 was premature and too eager. Easy in hindsight.
Wonder what's pulling this further down - are investors questioning if this has further ramifications?
It's a long-term play for me, but was hoping for positive trading momentum from the RUA Medical unit. Interested in others' thoughts
Wonder how Elliott will play it? They were buying in the low 600p through summer and saw value presumably in a break up of products and services. I'd speculate they'd want a better return than ~20%. As would I.
LIBERUM CUTS CLINIGEN PRICE TARGET TO 780 (800) PENCE - 'BUY'
Are people starting to focus on services now today's news is out there? I'm confident here and mindful of this statement from the results...
"The outlook for Services is positive with a continued strong pipeline and a good number of new high value projects to deliver revenues in FY2022. There are currently more than 350 opportunities across the pipeline with a combined value of more than £80m"
Rather misleading RNS headline!
Agree patience is key and also that cash position should have risen substantially.
Cellular pathology and genetic sequencing a huge opportunities in the future and if the current COVID testing windfall allowed them to acquire business in those areas it paints a rosy picture both short and long-term.
PCR testing back for travel and we have the best value day 2 test on the market according to Which?
£110m MC, below IPO. But with sales growing to approx. £85m this year from £50m. With a growing cash war chest, last noted at £17m.
So..... Am I missing something obvious?
Why is this so under the radar/unloved?
From the boss in the interims:
"We expect the focus of acquisitions to be similar or complementary businesses most likely relevant to the Healthcare Diagnostics (with cellular pathology and precision medicine targets being of particular interest) and Genomics business units."
SBI will use the testing profits to push the business on.